$DCTH
Delcath Systems Inc

2020 Q4 Form 10-K Financial Statement

#000156459021016962 Filed on March 31, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2020 2019 Q4
Revenue $510.0K $1.650M $520.0K
YoY Change -1.92% 4.43% -49.02%
Cost Of Revenue $210.0K $640.0K $280.0K
YoY Change -25.0% -10.99% -31.71%
Gross Profit $300.0K $1.010M $240.0K
YoY Change 25.0% 17.44% -60.66%
Gross Profit Margin 58.82% 61.21% 46.15%
Selling, General & Admin $4.540M $11.11M $2.080M
YoY Change 118.27% -1.52% -17.79%
% of Gross Profit 1513.33% 1099.8% 866.67%
Research & Development $2.740M $11.20M $2.700M
YoY Change 1.48% 18.02% -53.13%
% of Gross Profit 913.33% 1108.91% 1125.0%
Depreciation & Amortization $40.00K $167.0K $40.00K
YoY Change 0.0% -21.23% -60.0%
% of Gross Profit 13.33% 16.53% 16.67%
Operating Expenses $7.280M $11.11M $4.780M
YoY Change 52.3% -46.52% -42.41%
Operating Profit -$6.980M -$21.30M -$4.540M
YoY Change 53.74% 7.01% -40.96%
Interest Expense -$20.00K -$3.010M $17.03M
YoY Change -100.12% -127.29% -622.39%
% of Operating Profit
Other Income/Expense, Net -$30.00K $150.0K $0.00
YoY Change -100.0%
Pretax Income -$7.030M -$23.64M $12.49M
YoY Change -156.29% 384.29% -214.9%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$7.030M -$24.16M $12.49M
YoY Change -156.29% 172.07% -214.9%
Net Earnings / Revenue -1378.43% -1464.24% 2401.92%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.423M -$8.35 $416.3M
COMMON SHARES
Basic Shares Outstanding 2.898M 21.98M
Diluted Shares Outstanding 2.898M

Balance Sheet

Concept 2020 Q4 2020 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.58M $28.58M $10.00M
YoY Change 185.8% 185.8% 296.83%
Cash & Equivalents $28.58M $28.58M $10.00M
Short-Term Investments
Other Short-Term Assets $2.850M $2.850M $1.940M
YoY Change 46.91% 46.91% 40.58%
Inventory $855.0K $860.0K $654.0K
Prepaid Expenses
Receivables $57.00K $60.00K $21.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $32.34M $32.34M $12.62M
YoY Change 156.3% 156.26% 113.16%
LONG-TERM ASSETS
Property, Plant & Equipment $1.351M $2.300M $735.0K
YoY Change 83.81% 43.75% -20.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $2.297M $2.300M $1.595M
YoY Change 44.01% 44.65% 72.43%
TOTAL ASSETS
Total Short-Term Assets $32.34M $32.34M $12.62M
Total Long-Term Assets $2.297M $2.300M $1.595M
Total Assets $34.64M $34.64M $14.21M
YoY Change 143.7% 143.77% 107.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.774M $1.770M $4.533M
YoY Change -60.86% -60.93% -41.24%
Accrued Expenses $4.859M $5.740M $6.947M
YoY Change -30.06% -24.57% -12.77%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.000M $2.000M $0.00
YoY Change -100.0%
Total Short-Term Liabilities $10.04M $10.04M $15.99M
YoY Change -37.26% -37.21% -9.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $2.000M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $2.520M $2.520M $0.00
YoY Change -2.33% -100.0%
Total Long-Term Liabilities $2.520M $2.520M $0.00
YoY Change -44.98% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.04M $10.04M $15.99M
Total Long-Term Liabilities $2.520M $2.520M $0.00
Total Liabilities $12.56M $12.56M $20.57M
YoY Change -38.95% -38.94% -5.57%
SHAREHOLDERS EQUITY
Retained Earnings -$395.3M -$371.2M
YoY Change 6.51% 7.88%
Common Stock $60.00K $1.000K
YoY Change 5900.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.08M $22.08M -$6.357M
YoY Change
Total Liabilities & Shareholders Equity $34.64M $34.64M $14.21M
YoY Change 143.7% 143.77% 107.66%

Cashflow Statement

Concept 2020 Q4 2020 2019 Q4
OPERATING ACTIVITIES
Net Income -$7.030M -$24.16M $12.49M
YoY Change -156.29% 172.07% -214.9%
Depreciation, Depletion And Amortization $40.00K $167.0K $40.00K
YoY Change 0.0% -21.23% -60.0%
Cash From Operating Activities -$4.600M -$22.87M -$5.370M
YoY Change -14.34% -3.47% 191.85%
INVESTING ACTIVITIES
Capital Expenditures -$70.00K $782.0K -$20.00K
YoY Change 250.0% 3158.33% 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$70.00K -$782.0K -$20.00K
YoY Change 250.0% 3158.33% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $230.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 22.45M 42.36M -20.00K
YoY Change -112350.0% 39.76% -99.53%
NET CHANGE
Cash From Operating Activities -4.600M -22.87M -5.370M
Cash From Investing Activities -70.00K -782.0K -20.00K
Cash From Financing Activities 22.45M 42.36M -20.00K
Net Change In Cash 17.78M 18.57M -5.410M
YoY Change -428.65% 181.15% -11.89%
FREE CASH FLOW
Cash From Operating Activities -$4.600M -$22.87M -$5.370M
Capital Expenditures -$70.00K $782.0K -$20.00K
Free Cash Flow -$4.530M -$23.65M -$5.350M
YoY Change -15.33% -0.27% 193.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28575000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10002000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
181000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
181000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
57000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21000
CY2020Q4 us-gaap Inventory Net
InventoryNet
855000
CY2019Q4 us-gaap Inventory Net
InventoryNet
654000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2670000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1759000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
32338000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
12617000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1351000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
735000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
946000
CY2020 us-gaap Cost Of Revenue
CostOfRevenue
640000
CY2019 us-gaap Cost Of Revenue
CostOfRevenue
719000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
860000
CY2020Q4 us-gaap Assets
Assets
34635000
CY2019Q4 us-gaap Assets
Assets
14212000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1774000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4533000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5241000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6947000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
525000
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
482000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
495000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
664000
CY2020Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2000000
CY2019Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3368000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10035000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15994000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2072000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2378000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
450000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
197000
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0
CY2019Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
2000000
CY2020Q4 us-gaap Liabilities
Liabilities
12557000
CY2019Q4 us-gaap Liabilities
Liabilities
20569000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
60000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
417449000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
364785000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-395327000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-371171000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-104000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
28000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22078000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-6357000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34635000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14212000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
20631
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
41517
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
20631
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
41517
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5996101
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-21303000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-19908000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2832000
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-17493000
CY2019 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
8879000
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.35
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-342.83
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67091
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5996101
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67091
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11108000
CY2020 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
154000
CY2019 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2000
CY2020 dcth Warrants Down Round Feature Increase Decrease In Equity Amount
WarrantsDownRoundFeatureIncreaseDecreaseInEquityAmount
55000
CY2020 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
24211000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2897827
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25900
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2897827
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25900
CY2019Q4 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
1:700
CY2019Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.00142
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3505000
CY2020 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
406000
CY2020 dcth Shares Settled For Accrued Compensation Value
SharesSettledForAccruedCompensationValue
230000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-1000
CY2020 dcth Adjustment To Additional Paid In Capital Registration Of Preferred Stock And Related Warrants
AdjustmentToAdditionalPaidInCapitalRegistrationOfPreferredStockAndRelatedWarrants
-106000
CY2020 dcth Adjustments To Additional Paid In Capital Fair Value Of Warrants Reclassified From Liability To Equity
AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrantsReclassifiedFromLiabilityToEquity
6200000
CY2020 dcth Stock Issued During Period Value Exercise Of Warrants For Common Stock
StockIssuedDuringPeriodValueExerciseOfWarrantsForCommonStock
1858000
CY2020 dcth Issuance Of Common Stock And Warrants In Public Offering
IssuanceOfCommonStockAndWarrantsInPublicOffering
19378000
CY2020 dcth Atm Offering
ATMOffering
866000
CY2020 dcth Issuance Of Common Stock Confidentially Marketed Public Offering
IssuanceOfCommonStockConfidentiallyMarketedPublicOffering
20387000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-132000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-14939000
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
273000
CY2019 dcth Stock Issued During Period Value Exchange Of Warrants For Common Stock
StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonStock
13000
CY2019 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
20844000
CY2019 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-22000
CY2020Q2 dcth Gross Proceeds Of Public Offering
GrossProceedsOfPublicOffering
21996000
CY2020Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2618000
CY2020Q4 dcth Gross Proceeds Of Public Offering
GrossProceedsOfPublicOffering
22247000
CY2020Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1861000
CY2020 dcth Stock Option Compensation Income Expense
StockOptionCompensationIncomeExpense
3505000
CY2019 dcth Stock Option Compensation Income Expense
StockOptionCompensationIncomeExpense
273000
CY2020 dcth Restricted Stock Compensation Income Expense
RestrictedStockCompensationIncomeExpense
406000
CY2019 dcth Restricted Stock Compensation Income Expense
RestrictedStockCompensationIncomeExpense
4000
CY2020 us-gaap Depreciation
Depreciation
167000
CY2019 us-gaap Depreciation
Depreciation
212000
CY2020 dcth Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
25000
CY2019 dcth Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
37000
CY2020 dcth Interest Income Earned On Money Market And Operating Accounts
InterestIncomeEarnedOnMoneyMarketAndOperatingAccounts
1000
CY2019 dcth Interest Income Earned On Money Market And Operating Accounts
InterestIncomeEarnedOnMoneyMarketAndOperatingAccounts
11000
CY2020 dcth Equitization Of Expenses
EquitizationOfExpenses
0
CY2019 dcth Equitization Of Expenses
EquitizationOfExpenses
1474000
CY2020 dcth Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
0
CY2019 dcth Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
1715000
CY2020 us-gaap Paid In Kind Interest
PaidInKindInterest
160000
CY2019 us-gaap Paid In Kind Interest
PaidInKindInterest
74000
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
4467000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
910000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
807000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
36000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-497000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
201000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-204000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4396000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4350000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-263000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-479000
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0
CY2019 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-627000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22868000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23689000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
782000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-782000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24000
CY2020 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2019 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
3719000
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
26000
CY2019 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
39000
CY2020 us-gaap Payments Of Capital Distribution
PaymentsOfCapitalDistribution
106000
CY2019 us-gaap Payments Of Capital Distribution
PaymentsOfCapitalDistribution
0
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1000
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1858000
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42355000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30305000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-132000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18573000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6606000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10183000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3577000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28756000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
11000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
0
CY2020 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
21000
CY2019 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2020 dcth Reclassification Of Warrants From Liability To Equity
ReclassificationOfWarrantsFromLiabilityToEquity
6200000
CY2019 dcth Reclassification Of Warrants From Liability To Equity
ReclassificationOfWarrantsFromLiabilityToEquity
0
CY2020 us-gaap Stock Issued1
StockIssued1
0
CY2019 us-gaap Stock Issued1
StockIssued1
12572000
CY2020 dcth Non Cash Activities Fair Value Of Warrants Issued
NonCashActivitiesFairValueOfWarrantsIssued
0
CY2019 dcth Non Cash Activities Fair Value Of Warrants Issued
NonCashActivitiesFairValueOfWarrantsIssued
20844000
CY2020 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0
CY2019 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
1652000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
729000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
874000
CY2020 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
781000
CY2019 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
548000
CY2020 dcth Issuance Of Restricted Stock For2019 Bonuses Due To Executive Officers
IssuanceOfRestrictedStockFor2019BonusesDueToExecutiveOfficers
230000
CY2019 dcth Issuance Of Restricted Stock For2019 Bonuses Due To Executive Officers
IssuanceOfRestrictedStockFor2019BonusesDueToExecutiveOfficers
0
CY2020 us-gaap Basis Of Accounting
BasisOfAccounting
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Basis of Consolidated Financial Statement Presentation</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting and financial reporting policies of the Company conform to generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). The preparation of consolidated financial statements in conformity with GAAP requires management to make assumptions and estimates that impact the amounts reported in the Company&#8217;s consolidated financial statements. The consolidated financial statements include the accounts of all entities controlled by Delcath. All significant inter-company accounts and transactions are eliminated.</p> <p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reverse Stock Splits</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All share numbers presented in these financial statements, including these footnotes reflect <font style="color:#000000;">a one-for seven hundred (1:700) reverse stock split effected on December 24, 2019</font>.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#8217;s consolidated balance sheets and the amount of revenues and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for derivative instrument liabilities, stock-based compensation, valuation of inventory, impairment of long-lived assets, income taxes and operating expense accruals. Such assumptions and estimates are subject to change in the future as additional information becomes available or as circumstances are modified. Actual results could differ from these estimates.</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
CY2020 dcth Maximum Period Of Investments With Original Maturities From Date Of Acquisition To Be Cash Equivalents
MaximumPeriodOfInvestmentsWithOriginalMaturitiesFromDateOfAcquisitionToBeCashEquivalents
P3M
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7524574
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3693749
CY2020Q4 dcth Letters Of Credit Restricted Cash
LettersOfCreditRestrictedCash
131000
CY2019Q4 dcth Letters Of Credit Restricted Cash
LettersOfCreditRestrictedCash
131000
CY2020Q4 dcth Security For Credit Cards Restricted Cash
SecurityForCreditCardsRestrictedCash
50000
CY2019Q4 dcth Security For Credit Cards Restricted Cash
SecurityForCreditCardsRestrictedCash
50000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
435000
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
375000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
420000
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
279000
CY2020Q4 dcth Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1497000
CY2019Q4 dcth Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
725000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
845000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
589000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
328000
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
445000
CY2020Q4 dcth Maximum Percentage Of Prepaid Expenses And Other Current Assets
MaximumPercentageOfPrepaidExpensesAndOtherCurrentAssets
0.05
CY2019Q4 dcth Maximum Percentage Of Prepaid Expenses And Other Current Assets
MaximumPercentageOfPrepaidExpensesAndOtherCurrentAssets
0.05
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6064000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5246000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4713000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4511000
CY2020Q3 dcth Exercised Option To Purchase
ExercisedOptionToPurchase
460300
CY2020Q4 dcth Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
2698000
CY2019Q4 dcth Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
2497000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1598000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3525000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
945000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
925000
CY2020Q4 dcth Maximum Percentage Of Current Liabilities Accrued
MaximumPercentageOfCurrentLiabilitiesAccrued
0.05
CY2019Q4 dcth Maximum Percentage Of Current Liabilities Accrued
MaximumPercentageOfCurrentLiabilitiesAccrued
0.05
CY2020Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
699000
CY2020 dcth Financing Lease Cost
FinancingLeaseCost
27000
CY2020 us-gaap Sublease Income
SubleaseIncome
206000
CY2020 us-gaap Lease Cost
LeaseCost
520000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
699000
CY2020 us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
206000
CY2020 dcth Finance Lease Principal Payment On Liability
FinanceLeasePrincipalPaymentOnLiability
26000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
549000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
406000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
67000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1022000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
77000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
945000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2020Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
10.00
CY2020 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
2084507
CY2019 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
13455
CY2020 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
72976
CY2019 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
20
CY2020Q4 us-gaap Equity Fair Value Disclosure
EquityFairValueDisclosure
636000
CY2019Q4 us-gaap Equity Fair Value Disclosure
EquityFairValueDisclosure
4000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
230000
CY2020 dcth Stock Issued During Period Shares Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants
6000
CY2019 dcth Stock Issued During Period Shares Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants
11285
CY2020 dcth Stock Issued During Period Shares Associated Other Warrants
StockIssuedDuringPeriodSharesAssociatedOtherWarrants
185803
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
92
CY2019Q2 dcth Purchase Of Warrants
PurchaseOfWarrants
82521
CY2019Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
170
CY2019Q2 dcth Loss In Exchange Of Common Stock With Warrants
LossInExchangeOfCommonStockWithWarrants
6000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M7D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.8100
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.4763
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0027
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0251
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0040
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0259
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.41
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
181.41
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1640
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1078000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1141
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1078499
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
87834
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
196.70
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.60
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
196.70
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.68
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.57
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y9M18D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y9M18D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6012000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
494000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8824000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P9Y9M18D
CY2020 dcth Share Based Compensation Income Expense
ShareBasedCompensationIncomeExpense
3505000
CY2019 dcth Share Based Compensation Income Expense
ShareBasedCompensationIncomeExpense
273000
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1826608
CY2020 dcth Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
2601900
CY2020 dcth Class Of Warrant Or Right Exercises In Period
ClassOfWarrantOrRightExercisesInPeriod
191803
CY2020 dcth Class Of Warrant Or Right Expired In Period
ClassOfWarrantOrRightExpiredInPeriod
18
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4236687
CY2020Q4 dcth Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
4236687
CY2019Q4 dcth Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
23.04
CY2020 dcth Class Of Warrant Or Right Weighted Average Exercise Price Issued
ClassOfWarrantOrRightWeightedAverageExercisePriceIssued
8.55
CY2020 dcth Class Of Warrant Or Right Weighted Average Exercise Price Exercises In Period
ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod
9.69
CY2020 dcth Class Of Warrant Or Right Weighted Average Exercise Price Expirations In Period
ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod
10.00
CY2020Q4 dcth Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
9.13
CY2020Q4 dcth Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
9.13
CY2020 dcth Class Of Warrant Or Right Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
P4Y2M12D
CY2020 dcth Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm
P4Y2M12D
CY2020Q4 dcth Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
37261000
CY2020Q4 dcth Class Of Warrant Or Right Exercisable Intrinsic Value
ClassOfWarrantOrRightExercisableIntrinsicValue
37261000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.00
CY2018Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
33000
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
17498000
CY2019 dcth Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Reclassified From Liability To Equity
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassifiedFromLiabilityToEquity
11000
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
20844000
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3368000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-2832000
CY2020 dcth Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Reclassified From Liability To Equity
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassifiedFromLiabilityToEquity
6200000
CY2020Q4 us-gaap Deferred Compensation Arrangement With Individual Description
DeferredCompensationArrangementWithIndividualDescription
Mr. Michel shall also be entitled to: (a) a severance payment equal in the aggregate to twelve (12) months of his annual base salary at the time of termination, payable in twelve (12) equal monthly installments; and (b) specified continuing health plan benefits until the earlier of (i) the twelve (12) month anniversary of his termination date, (ii) the last day he’s eligible for coverage pursuant to COBRA or (iii) the date on which he becomes eligible for similar coverage from another employer.
CY2020 us-gaap Lessor Operating Lease Description
LessorOperatingLeaseDescription
the 2014 Sublease and 2015 Sublease were extended from May 31, 2020 to August 2, 2021, (ii) effective July 1, 2020, the leased premises under the 2015 Sublease would be expanded to include an additional 4,999 square feet of space, and (iii) effective July 1, 2020, the rent under the 2015 Sublease would increase from approximately $14.6 per month to $20.6 per month.
CY2020Q3 us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
May 31, 2020 to August 2, 2021
CY2020Q2 us-gaap Lease Cost
LeaseCost
0
CY2020Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-02-28
CY2020Q4 dcth Operating Lease Liability Future Minimum Sublease Rentals Due Next Twelve Months
OperatingLeaseLiabilityFutureMinimumSubleaseRentalsDueNextTwelveMonths
419000
CY2020Q4 dcth Operating Lease Liability Future Minimum Sublease Rentals Due Year Two
OperatingLeaseLiabilityFutureMinimumSubleaseRentalsDueYearTwo
406000
CY2020Q4 dcth Operating Lease Liability Future Minimum Sublease Rentals Due
OperatingLeaseLiabilityFutureMinimumSubleaseRentalsDue
68000
CY2020 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
423000
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
529000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-23643000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-4882000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-513000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-3997000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-24156000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-8879000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
5073000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
1865000
CY2020 dcth Income Tax Reconciliation Nondeductible Expense Interest
IncomeTaxReconciliationNondeductibleExpenseInterest
-315000
CY2019 dcth Income Tax Reconciliation Derivative Charge
IncomeTaxReconciliationDerivativeCharge
3674000
CY2020 dcth Valuation Allowance Deferred Tax Asset Change In Amount Charged To Costs And Expenses
ValuationAllowanceDeferredTaxAssetChangeInAmountChargedToCostsAndExpenses
6281000
CY2019 dcth Valuation Allowance Deferred Tax Asset Change In Amount Charged To Costs And Expenses
ValuationAllowanceDeferredTaxAssetChangeInAmountChargedToCostsAndExpenses
3512000
CY2020 dcth Income Tax Reconciliation Derivative Charge
IncomeTaxReconciliationDerivativeCharge
-595000
CY2019 dcth Income Tax Reconciliation Nondeductible Expense Interest
IncomeTaxReconciliationNondeductibleExpenseInterest
-994000
CY2019 dcth Income Tax Reconciliation Loss On Extinguishment Of Debt
IncomeTaxReconciliationLossOnExtinguishmentOfDebt
-361000
CY2020 dcth Income Tax Rate Reconciliation State Operating Loss Carryforwards
IncomeTaxRateReconciliationStateOperatingLossCarryforwards
11000
CY2019 dcth Income Tax Rate Reconciliation State Operating Loss Carryforwards
IncomeTaxRateReconciliationStateOperatingLossCarryforwards
-1477000
CY2019 dcth Income Tax Reconciliation Federal Tax Credits
IncomeTaxReconciliationFederalTaxCredits
324000
CY2020 dcth Income Tax Reconciliation Branch Income
IncomeTaxReconciliationBranchIncome
238000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1788000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1461000
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
238000
CY2019 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-664000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-308000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
14999000
CY2020Q4 dcth Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
265000
CY2019Q4 dcth Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
206000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
265000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
206000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21332000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14793000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 dcth Valuation Allowance Deferred Tax Asset Percentage
ValuationAllowanceDeferredTaxAssetPercentage
1.00
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-6540000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
166000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
316000
CY2020 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-15000
CY2019 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
16000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
796000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
84000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
361000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
346000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
135000
CY2020Q4 dcth Deferred Tax Assets Lease Obligations
DeferredTaxAssetsLeaseObligations
265000
CY2019Q4 dcth Deferred Tax Assets Lease Obligations
DeferredTaxAssetsLeaseObligations
206000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
87000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
72000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19742000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14502000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21597000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-3428000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11364000
CY2020 dcth Valuation Allowance Deferred Tax Asset Change In Amount Charged To Other Comprehensive Income
ValuationAllowanceDeferredTaxAssetChangeInAmountChargedToOtherComprehensiveIncome
258000
CY2019 dcth Valuation Allowance Deferred Tax Asset Change In Amount Charged To Other Comprehensive Income
ValuationAllowanceDeferredTaxAssetChangeInAmountChargedToOtherComprehensiveIncome
-83000

Files In Submission

Name View Source Status
0001564590-21-016962-index-headers.html Edgar Link pending
0001564590-21-016962-index.html Edgar Link pending
0001564590-21-016962.txt Edgar Link pending
0001564590-21-016962-xbrl.zip Edgar Link pending
dcth-10k_20201231.htm Edgar Link pending
dcth-20201231.xml Edgar Link completed
dcth-20201231.xsd Edgar Link pending
dcth-20201231_cal.xml Edgar Link unprocessable
dcth-20201231_def.xml Edgar Link unprocessable
dcth-20201231_lab.xml Edgar Link unprocessable
dcth-20201231_pre.xml Edgar Link unprocessable
dcth-ex21_127.htm Edgar Link pending
dcth-ex231_420.htm Edgar Link pending
dcth-ex311_7.htm Edgar Link pending
dcth-ex312_6.htm Edgar Link pending
dcth-ex321_10.htm Edgar Link pending
dcth-ex322_9.htm Edgar Link pending
dcth-ex49_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending